Damon Runyon Researchers

Meet Our Scientists
Max Jan, MD, PhD

Genetically engineered immune cell therapies have emerged as breakthroughs in the treatment of certain blood cancers. However, these advances have been limited to the minority of cancers that express a cell surface protein on all tumor cells; this protein is absent from essential normal tissues and can be recognized and targeted by therapeutic immune cells. Dr. Jan seeks to develop synthetic biology tools to engineer immune cells to recognize the heterogeneous tumor proteins present on many advanced cancers and then activate the body's tumor clearance mechanisms. His goal is to develop cell therapy candidates for direct translation to the care of people with advanced prostate cancer.

Project title: "Programming next-generation NK cell therapies using targeted protein degradation"
Institution: Massachusetts General Hospital
Award Program: Innovator
Cancer Type: Prostate, All Cancers
Research Area: Immunotherapy